Multisystem inflammatory syndrome drug treatment in countries with different income profiles: a scoping review
Objective: The purpose of this study was to map and describe the studies that have investigated therapeutic alternatives for the management of paediatric multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19. Considering the origin of the studies performed (low-, middle- and...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1228986/full |
| _version_ | 1797738313700868096 |
|---|---|
| author | Luis Phillipe Nagem Lopes Lidiane Gomes da Cunha Alice Ramos Oliveira Silva Marcelo Gerardin Poirot Land Adriana Rodrigues Fonseca Luciane Cruz Lopes Elisangela Costa Lima |
| author_facet | Luis Phillipe Nagem Lopes Lidiane Gomes da Cunha Alice Ramos Oliveira Silva Marcelo Gerardin Poirot Land Adriana Rodrigues Fonseca Luciane Cruz Lopes Elisangela Costa Lima |
| author_sort | Luis Phillipe Nagem Lopes |
| collection | DOAJ |
| description | Objective: The purpose of this study was to map and describe the studies that have investigated therapeutic alternatives for the management of paediatric multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19. Considering the origin of the studies performed (low-, middle- and high-income countries), a systematic scoping review was conducted with primary studies that reported the use of medications for the treatment of patients with MIS-C.Sources: The searches were performed in MEDLINE, Embase, Lilacs, Epistemonikos, CINAHL, and CENTRAL, in the grey literature (theses and dissertations from CAPES, ProQuest, and PROSPERO) and in clinical trial databases until May 2022. The selection and extraction of studies were performed independently by two reviewers.Summary of the findings: A total of 173 studies were included, most of which were published as case reports or series. No randomized controlled clinical trials (RCTs) were identified. The investigated drugs were immunoglobulins, glucocorticoids, monoclonal antibodies, anticoagulants, and antiplatelet agents.Conclusion: The dosages, when reported, were heterogeneous among the studies. The ethnicity and comorbidity of the participants were poorly reported. Monoclonal antibodies, drugs with higher costs, were mostly described in studies of high-income countries. |
| first_indexed | 2024-03-12T13:42:02Z |
| format | Article |
| id | doaj.art-41d341a2879b47ddb6716d7edee444de |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-12T13:42:02Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-41d341a2879b47ddb6716d7edee444de2023-08-23T14:39:35ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-08-011410.3389/fphar.2023.12289861228986Multisystem inflammatory syndrome drug treatment in countries with different income profiles: a scoping reviewLuis Phillipe Nagem Lopes0Lidiane Gomes da Cunha1Alice Ramos Oliveira Silva2Marcelo Gerardin Poirot Land3Adriana Rodrigues Fonseca4Luciane Cruz Lopes5Elisangela Costa Lima6Post-Graduate Program in Pharmaceutical Sciences, University of Sorocaba, São Paulo, BrazilFaculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilFaculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilPost-Graduate Program in Saúde Materno Infantil, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilPost-Graduate Program in Saúde Materno Infantil, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilPost-Graduate Program in Pharmaceutical Sciences, University of Sorocaba, São Paulo, BrazilFaculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilObjective: The purpose of this study was to map and describe the studies that have investigated therapeutic alternatives for the management of paediatric multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19. Considering the origin of the studies performed (low-, middle- and high-income countries), a systematic scoping review was conducted with primary studies that reported the use of medications for the treatment of patients with MIS-C.Sources: The searches were performed in MEDLINE, Embase, Lilacs, Epistemonikos, CINAHL, and CENTRAL, in the grey literature (theses and dissertations from CAPES, ProQuest, and PROSPERO) and in clinical trial databases until May 2022. The selection and extraction of studies were performed independently by two reviewers.Summary of the findings: A total of 173 studies were included, most of which were published as case reports or series. No randomized controlled clinical trials (RCTs) were identified. The investigated drugs were immunoglobulins, glucocorticoids, monoclonal antibodies, anticoagulants, and antiplatelet agents.Conclusion: The dosages, when reported, were heterogeneous among the studies. The ethnicity and comorbidity of the participants were poorly reported. Monoclonal antibodies, drugs with higher costs, were mostly described in studies of high-income countries.https://www.frontiersin.org/articles/10.3389/fphar.2023.1228986/fullmultisystem inflammatory syndrome in childrensocial determinants of healthCOVID-19high-cost medicinespediatrics |
| spellingShingle | Luis Phillipe Nagem Lopes Lidiane Gomes da Cunha Alice Ramos Oliveira Silva Marcelo Gerardin Poirot Land Adriana Rodrigues Fonseca Luciane Cruz Lopes Elisangela Costa Lima Multisystem inflammatory syndrome drug treatment in countries with different income profiles: a scoping review Frontiers in Pharmacology multisystem inflammatory syndrome in children social determinants of health COVID-19 high-cost medicines pediatrics |
| title | Multisystem inflammatory syndrome drug treatment in countries with different income profiles: a scoping review |
| title_full | Multisystem inflammatory syndrome drug treatment in countries with different income profiles: a scoping review |
| title_fullStr | Multisystem inflammatory syndrome drug treatment in countries with different income profiles: a scoping review |
| title_full_unstemmed | Multisystem inflammatory syndrome drug treatment in countries with different income profiles: a scoping review |
| title_short | Multisystem inflammatory syndrome drug treatment in countries with different income profiles: a scoping review |
| title_sort | multisystem inflammatory syndrome drug treatment in countries with different income profiles a scoping review |
| topic | multisystem inflammatory syndrome in children social determinants of health COVID-19 high-cost medicines pediatrics |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1228986/full |
| work_keys_str_mv | AT luisphillipenagemlopes multisysteminflammatorysyndromedrugtreatmentincountrieswithdifferentincomeprofilesascopingreview AT lidianegomesdacunha multisysteminflammatorysyndromedrugtreatmentincountrieswithdifferentincomeprofilesascopingreview AT aliceramosoliveirasilva multisysteminflammatorysyndromedrugtreatmentincountrieswithdifferentincomeprofilesascopingreview AT marcelogerardinpoirotland multisysteminflammatorysyndromedrugtreatmentincountrieswithdifferentincomeprofilesascopingreview AT adrianarodriguesfonseca multisysteminflammatorysyndromedrugtreatmentincountrieswithdifferentincomeprofilesascopingreview AT lucianecruzlopes multisysteminflammatorysyndromedrugtreatmentincountrieswithdifferentincomeprofilesascopingreview AT elisangelacostalima multisysteminflammatorysyndromedrugtreatmentincountrieswithdifferentincomeprofilesascopingreview |